Credit: (C) Erica Tandori
A research collaboration between Monash University and Lava Therapeutics details a novel immune-oncology approach for the potential treatment of cancer. Instrumental to the study was co-first author Dr Roeland Lameris from Amsterdam UMC and colleagues from the University of Melbourne.
Published in Nature Cancer, the study, co-led by Monash Biomedicine Discovery Institute’s ARC Laureate Fellow Professor Jamie Rossjohn and Dr Adam Shahine, highlights the synergy between an antibody fragment, known as a nanobody, that not only acts as a bridge helping to link together two key immune cell receptors but also takes advantage of their interaction, enabling the body to enhance its immune response to cancer.
These antibody fragments, denoted as nanobodies, act by targeting the interaction between a molecule known as CD1d and Natural Killer T cells (NKT) in a stable and long-lasting manner, against tumour samples of patients with multiple myeloma and acute myeloid leukemia.
The new findings will serve as a model for the potential generation of new and effective therapies against a broad range of cancers.
Using the Australian Synchrotron, the team at Monash University provided detailed atomic insight into how the nanobodies exerted their effect on immune cells in a cancer model. “We were able to precisely visualise how the nanobody simultaneously recognised CD1d and the NKT TCR, thereby providing a molecular basis for their anti-tumour properties,” Professor Rossjohn stated.
Hans van der Vliet, professor in medical oncology at Amsterdam UMC and chief scientific officer of Lava Therapeutics, says “By targeting and boosting natural immune cells that are inherent in all humans, such as NKT cells and gamma-delta T cells, for an enhanced therapeutic effect, we believe our approach could ultimately translate into a broadly applicable immunotherapeutic approach for a range of cancer indications.”
“This collaborative work paves the way for rationally developing improved therapeutics to treat a range of cancers” said co-first author Dr Shahine.
About the Monash Biomedicine Discovery Institute at Monash University
Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Spanning six discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection and Immunity, Metabolic Disease and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.
Read the full paper in Nature Cancer titled: “A single domain bispecific antibody targeting CD1d and the NKT T cell receptor induces a potent anti-tumour response”
Media Enquiries please contact:
Wendy Smith – Monash Media
T: +61 (0) 425 725 836
Related Journal Article